Acute ingestion of doses in excess of 10 times the maximum therapeutic dose has been reported. In addition to those events reported as Undesirable Effects, overdose has resulted in symptoms including drowsiness, loss of consciousness and/or ECG changes such as conduction disturbances (including QRS prolongation), arrhythmias and tachycardia. QTc prolongation has also been reported but was generally seen in conjunction with QRS prolongation and increased heart rate. Although most patients recovered without sequelae, deaths associated with bupropion have been reported rarely in patients ingesting large overdoses of the drug.
Treatment: In the event of overdose, hospitalisation is advised. ECG and vital signs should be monitored.
Ensure an adequate airway, oxygenation and ventilation. The use of activated charcoal is recommended. No specific antidote for bupropion is known. Further management should be as clinically indicated.
Budeprionsr is contraindicated in patients with a current seizure disorder or any history of seizures.
Budeprionsr is contraindicated in patients with a known central nervous system (CNS) tumour.
Budeprionsr is contraindicated in patients who, at any time during treatment, are undergoing abrupt withdrawal from alcohol or any medicinal product known to be associated with risk of seizures on withdrawal (in particular benzodiazepines and benzodiazepine-like agents).
Budeprionsr is contraindicated in patients with a current or previous diagnosis of bulimia or anorexia nervosa.
Budeprionsr is contraindicated for use in patients with severe hepatic cirrhosis.
Concomitant use of Budeprionsr and monoamine oxidase inhibitors (MAOIs) is contraindicated. At least 14 days should elapse between discontinuation of irreversible MAOIs and initiation of treatment with Budeprionsr. For reversible MAOIs, a 24 hour period is sufficient.
Budeprionsr is contraindicated in patients with a history of bipolar disorder as it may precipitate a manic episode during the depressed phase of their illness.
Budeprionsr should not be administered to patients being treated with any other medicinal product containing bupropion as the incidence of seizures is dose dependent and to avoid overdosage.
Not applicable.
The list below provides information on the undesirable effects identified from clinical experience, categorised by incidence and System Organ Class body system. It is important to note that smoking cessation is often associated with nicotine withdrawal symptoms (e.g. agitation, insomnia, tremor, sweating), some of which are also recognised as adverse events associated with Budeprionsr.
Undesirable effects are ranked under headings of frequency using the following convention; very common (>1/10); common (>1/100, <1/10); uncommon (>1/1,000, <1/100); rare (>1/10000, <1/1,000); very rare (<1/10000); not known (cannot be estimated from the available data).
| Blood and lymphatic system disorders | Not known | Anaemia, leucopenia and thrombocytopenia |
| Immune system disorders* | Common | Hypersensitivity reactions such as urticaria |
| Rare | More severe hypersensitivity reactions including angioedema, dyspnoea/bronchospasm and anaphylactic shock. Arthralgia, myalgia and fever have also been reported in association with rash and other symptoms suggestive of delayed hypersensitivity. These symptoms may resemble serum sickness | |
| Metabolism and nutrition disorders | Uncommon | Anorexia |
| Rare | Blood glucose disturbances | |
| Not known | hyponatraemia | |
| Psychiatric disorders | Very common | Insomnia |
| Common | Depression , agitation, anxiety | |
| Uncommon | Confusion | |
| Rare | Irritability, hostility, hallucinations, depersonalisation, abnormal dreams including nightmares | |
| Very rare | Delusions, paranoid ideation, restlessness, aggression | |
| Not known | Suicidal ideation and suicidal behaviour***, psychosis | |
| Nervous system disorders | Common | Tremor, concentration disturbance, headache, dizziness, taste disorders |
| Rare | Seizures (see below)**, dystonia, ataxia, Parkinsonism, incoordination, memory impairment, paraesthesia, syncope | |
| Eye disorders | Uncommon | Visual disturbance |
| Ear and labyrinth disorders | Uncommon | Tinnitus |
| Cardiac disorders | Uncommon | Tachycardia |
| Rare | Palpitations | |
| Vascular disorders | Uncommon | Increased blood pressure (sometimes severe), flushing |
| Rare | Vasodilation, postural hypotension | |
| Gastrointestinal disorders | Common | Dry mouth, gastrointestinal disturbance including nausea and vomiting, abdominal pain, constipation |
| Hepatobiliary disorders | Rare | Elevated liver enzymes, jaundice, hepatitis |
| Skin and subcutaneous tissue disorders* | Common | Rash, pruritus, sweating. |
| Rare | Erythema multiforme and Stevens Johnson syndrome have also been reported. Exacerbation of psoriasis | |
| Musculoskeletal and connective tissue disorders | Rare | Twitching |
| Renal and urinary disorders | Rare | Urinary frequency and/or retention |
| Very rare | Urinary incontinence | |
| General disorders and administration site conditions | Common | Fever |
| Uncommon | Chest pain, asthenia |
* Hypersensitivity may manifest as skin reactions. See “Immune system disorders†and “Skin and subcutaneous tissue disordersâ€.
**The incidence of seizures is approximately 0.1% (1/1,000). The most common type of seizures is generalised tonic-clonic seizures, a seizure type which can result in some cases in post-ictal confusion or memory impairment..
***Cases of suicidal ideation and suicidal behaviour have been reported during bupropion therapy.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard
Reproduction toxicity studies conducted in rats at exposures similar to those obtained at the maximum recommended human dose (based on systemic data on exposure) revealed no adverse effects on fertility, pregnancy and foetal development. Reproduction toxicity studies conducted in rabbits treated with doses up to 7 times the maximum recommended human dose based on a mg/m2 basis (no systemic data on exposures are available) only revealed a slight increase in skeletal variations (increased incidence of common anatomical variation of an accessory thoracic rib and delayed ossification of phalanges). Moreover at maternally toxic doses, a decrease of rabbits foetal weight was reported.
In animal experiments bupropion doses several times higher than therapeutic doses in humans caused, amongst others, the following dose-related symptoms: ataxia and convulsions in rats, general weakness, trembling and emesis in dogs and increased lethality in both species. Due to enzyme induction in animals but not in humans, systemic exposures in animals were similar to the systemic exposures seen in humans at the maximum recommended dose.
Liver changes are seen in animal studies but these reflect the action of a hepatic enzyme inducer. At recommended doses in humans, bupropion does not induce its own metabolism. This suggests that the hepatic findings in laboratory animals have only limited importance in the evaluation and risk assessment of bupropion.
Genotoxicity data indicate that bupropion is a weak bacterial mutagen, but not a mammalian mutagen, and therefore is of no concern as a human genotoxic agent. Mouse and rat studies confirm the absence of carcinogenicity in these species.
Budeprionsr tablets are indicated as an aid to smoking cessation in combination with motivational support in nicotine-dependent patients.
Pharmacotherapeutic group: Other antidepressants, ATC code: N06 AX12.
Mechanism of action
Bupropion is a selective inhibitor of the neuronal re-uptake of catecholamines (noradrenaline and dopamine) with minimal effect on the re-uptake of indolamines (serotonin) and does not inhibit either monoamine oxidase. The mechanism by which bupropion enhances the ability of patients to abstain from smoking is unknown.
However, it is presumed that this action is mediated by noradrenergic and/or dopaminergic mechanisms.
Clinical safety
The prospectively observed proportion of cardiac birth defects in pregnancies with prenatal exposure to bupropion in the first trimester in the international pregnancy register was 9/675 (1.3%).
In a retrospective study there was no greater proportion of congenital malformations or cardiovascular malformations amongst more than a thousand first trimester exposures to bupropion compared with the use of other antidepressants.
In a retrospective analysis using data from the National Birth Defects Prevention Study, a statistically significant association was observed between the occurrence of a left outflow tract heart defect in the infant and self-reported maternal bupropion use in early pregnancy. No association was observed between maternal bupropion use and any other type of cardiac defect or with all categories of heart defects combined.
A further analysis of data from the Slone Epidemiology Center Birth Defects Study found no statistically significant increase of left outflow tract heart defects with maternal bupropion use. However, a statistically significant association was observed for ventricular septal defects following the use of bupropion alone during the first trimester.
Absorption
After oral administration of 150 mg bupropion hydrochloride as a prolonged release tablet to healthy volunteers, maximum plasma concentrations (Cmax) of approximately 100 nanograms per ml are observed after about 2.5 to 3 hours. The AUC and Cmax values of bupropion and its active metabolites hydroxybupropion and threohydrobupropion increase dose proportionally over a dose range of 50-200 mg following single dosing and over a dose range of 300-450 mg/day following chronic dosing. The Cmax and AUC values of hydroxybupropion are approximately 3 and 14 times higher, respectively, than bupropion Cmax and AUC values. The Cmax of threohydrobupropion is comparable with the Cmax of bupropion, while the AUC of threohydrobupropion is approximately 5 times higher than that of bupropion. Peak plasma levels of hydroxybupropion and threohydrobupropion are reached after about 6 hours following administration of a single dose of bupropion. Plasma levels of erythrohydrobupropion (an isomer of threohydrobupropion, which is also active) are not quantifiable after single dosing with bupropion.
After chronic dosing with bupropion 150 mg bid, the Cmax of bupropion is similar to values reported after single dosing. For hydroxybupropion and threohydrobupropion, the Cmax values are higher (about 4 and 7 times respectively) at steady-state than after a single dosing. Plasma levels of erythrohydrobupropion are comparable to steady-state plasma levels of bupropion. Steady-state of bupropion and its metabolites is reached within 5-8 days. The absolute bioavailability of bupropion is not known; excretion data in urine, however, show that at least 87% of the dose of bupropion is absorbed.
Two studies with bupropion SR 150mg tablets in healthy volunteers suggest that exposure to bupropion may be increased when Budeprionsr tablets are taken with food. When taken following a high fat breakfast, peak plasma concentration of bupropion (Cmax) increased by 11% and 35% in the two studies, while the overall exposure to bupropion (AUC) increased by 16% and 19%.
Distribution
Bupropion is widely distributed with an apparent volume of distribution of approximately 2000 L.
Bupropion, hydroxybupropion and threohydrobupropion bind moderately to plasma proteins (84%, 77% and 42%, respectively). Bupropion and its active metabolites are excreted in human breast milk. Animal studies show that bupropion and its active metabolites pass the blood-brain barrier and the placenta.
Biotransformation
Bupropion is extensively metabolised in humans. Three pharmacologically active metabolites have been identified in plasma: hydroxybupropion and the amino-alcohol isomers, threohydrobupropion and erythrohydrobupropion. These may have clinical importance, as their plasma concentrations are as high or higher than those of bupropion. The active metabolites are further metabolised to inactive metabolites (some of which have not been fully characterised but may include conjugates) and excreted in the urine.
In vitro studies indicate that bupropion is metabolised to its major active metabolite hydroxybupropion primarily by the CYP2B6, while CYP1A2, 2A6, 2C9, 3A4 and 2E1 are less involved. In contrast, formation of threohydrobupropion involves carbonyl reduction but does not involve cytochrome P450 isoenzymes.
The inhibition potential of threohydrobupropion and erythrohydrobupropion towards cytochrome P450 has not been studied.
Bupropion and hydroxybupropion are both inhibitors of the CYP2D6 isoenzyme with Ki values of 21 and 13.3μM, respectively.
Following oral administration of a single 150-mg dose of bupropion, there was no difference in Cmax, half-life, Tmax, AUC, or clearance of bupropion or its major metabolites between smokers and non-smokers.
Bupropion has been shown to induce its own metabolism in animals following sub-chronic administration. In humans, there is no evidence of enzyme induction of bupropion or hydroxybupropion in volunteers or patients receiving recommended doses of bupropion hydrochloride for 10 to 45 days.
Elimination
Following oral administration of 200mg of 14C-bupropion in humans, 87% and 10% of the radioactive dose were recovered in the urine and faeces, respectively. The fraction of the dose of bupropion excreted unchanged was only 0.5%, a finding consistent with the extensive metabolism of bupropion. Less than 10% of this 14C dose was accounted for in the urine as active metabolites.
The mean apparent clearance following oral administration of bupropion hydrochloride is approximately 200 L/hr and the mean elimination half-life of bupropion is approximately 20 hours.
The elimination half-life of hydroxybupropion is approximately 20 hours. The elimination half-lives for threohydrobupropion and erythrohydrobupropion are longer (37 and 33 hours, respectively).
Special Patient Groups:
Patients with renal impairment
The elimination of bupropion and its active major metabolites may be reduced in patients with impaired renal function. Limited data in patients with end-stage renal failure or moderate to severely impaired renal function indicate that exposure to bupropion and/or its metabolites was increased.
Patients with hepatic impairment
The pharmacokinetics of bupropion and its active metabolites were not statistically significantly different in patients with mild to moderate cirrhosis when compared to healthy volunteers, although more variability was observed between individual patients. For patients with severe hepatic cirrhosis, the bupropion Cmax and AUC were substantially increased (mean difference approximately 70% and 3-fold, respectively) and more variable when compared to the values in healthy volunteers; the mean half-life was also longer (by approximately 40%). For hydroxybupropion, the mean Cmax was lower (by approximately 70%), the mean AUC tended to be higher (by approximately 30%), the median Tmax was later (by approximately 20 hrs), and the mean half-lives were longer (by approximately 4-fold) than in healthy volunteers. For threohydrobupropion and erythrohydrobupropion, the mean Cmax tended to be lower (by approximately 30%), the mean AUC tended to be higher (by approximately 50%), the median Tmax was later (by approximately 20 hrs), and the mean half-life was longer (by approximately 2-fold) than in healthy volunteers.
Older people
Pharmacokinetic studies in the elderly have shown variable results. A single dose study showed that the pharmacokinetics of bupropion and its metabolites in the elderly do not differ from those in the younger adults. Another pharmacokinetic study, single and multiple dose, has suggested that accumulation of bupropion and its metabolites may occur to a greater extent in the elderly. Clinical experience has not identified differences in tolerability between older and younger patients, but greater sensitivity in older patients cannot be ruled out.
Seizures
The recommended dose of Budeprionsr must not be exceeded, since bupropion is associated with a dose-related risk of seizure. At doses up to the maximum recommended daily dose (300mg of Budeprionsr daily), the incidence of seizures is approximately 0.1% (1/1,000).
There is an increased risk of seizures occurring with the use of Budeprionsr in the presence of predisposing risk factors which lower the seizure threshold. Budeprionsr must not be used in patients with predisposing risk factors unless there is a compelling clinical justification for which the potential medical benefit of smoking cessation outweighs the potential increased risk of seizure. In these patients, a maximum dose of 150mg daily should be considered for the duration of treatment.
All patients should be assessed for predisposing risk factors, which include:
- concomitant administration of other medicinal products known to lower the seizure threshold (e.g., antipsychotics, antidepressants, antimalarials, tramadol, theophylline, systemic steroids, quinolones and sedating antihistamines). For patients prescribed such medicinal products whilst taking Budeprionsr, a maximum dose of 150mg daily for the remainder of their treatment should be considered.
- alcohol abuse (see also section 4.3)
- history of head trauma
- diabetes treated with hypoglycaemics or insulin
- use of stimulants or anorectic products.
Budeprionsr should be discontinued and not recommenced in patients who experience a seizure while on treatment.
Interactions
Due to pharmacokinetic interactions plasma levels of bupropion or its metabolites may be altered, which may increase the potential for undesirable effects (e.g. dry mouth, insomnia, seizures). Therefore care should be taken when bupropion is given concomitantly with medicinal products which can induce or inhibit the metabolism of bupropion.
Bupropion inhibits metabolism by cytochrome P450 2D6. Caution is advised when medicinal products metabolised by this enzyme are administered concomitantly.
In the literature it has been shown that medications that inhibit CYP2D6 may lead to reduced concentrations of endoxifen which is the active metabolite of tamoxifen. Therefore the use of bupropion, which is an inhibitor of CYP2D6, should whenever possible be avoided during tamoxifen treatment.
Neuropsychiatry
Budeprionsr is a centrally-acting noradrenaline/dopamine reuptake inhibitor. Neuropsychiatric reactions have been reported. In particular, psychotic and manic symptomatology have been reported mainly in patients with a known history of psychiatric illness.
Depressed mood may be a symptom of nicotine withdrawal. Depression, rarely including suicidal ideation and behaviour (including suicide attempt), has been reported in patients undergoing a smoking cessation attempt. These symptoms have also been reported during Budeprionsr treatment, and generally occurred early during the treatment course.
Bupropion is indicated for the treatment of depression in some countries. A meta-analysis of placebo controlled clinical trials of antidepressant drugs in adults with major depressive disorder and other psychiatric disorders showed an increased risk of suicidal thinking and behaviour associated with antidepressant use compared to placebo in patients less than 25 years old.
Clinicians should be aware of the possible emergence of significant depressive symptomatology in patients undergoing a smoking cessation attempt, and should advise patients accordingly.
Data in animals suggest a potential for drug abuse. However, studies on abuse liability in humans and extensive clinical experience show that bupropion has low abuse potential.
Hypersensitivity
Budeprionsr should be discontinued if patients experience hypersensitivity reactions during treatment. Clinicians should be aware that symptoms may progress or recur following the discontinuation of Budeprionsr and should ensure symptomatic treatment is administered for an adequate length of time (at least one week). Symptoms typically include skin rash, pruritus, urticaria or chest pain but more severe reactions may include angioedema, dyspnoea/bronchospasm, anaphylactic shock, erythema multiforme or Stevens-Johnson Syndrome. Arthralgia, myalgia and fever have also been reported in association with rash and other symptoms suggestive of delayed hypersensitivity. These symptoms may resemble serum sickness. In most patients symptoms improved after stopping bupropion and initiating treatment with antihistamine or corticosteroids, and resolved over time.
Hypertension
In clinical practice, hypertension, which in some cases may be severe and require acute treatment, has been reported in patients receiving bupropion alone and in combination with nicotine replacement therapy. This has been observed in patients with and without pre-existing hypertension. A baseline blood pressure should be obtained at the start of treatment with subsequent monitoring, especially in patients with pre-existing hypertension. Consideration should be given to discontinuation of Budeprionsr if a clinically significant increase in blood pressure is observed.
Limited clinical trial data suggest that higher smoking cessation rates may be achieved by the combination use of Budeprionsr together with Nicotine Transdermal System (NTS). However, a higher rate of treatment-emergent hypertension was noted in the combination therapy group. If combination therapy with a NTS is used, caution must be exercised and weekly monitoring of blood pressure is recommended. Prior to initiation of combination therapy prescribers should consult the prescribing information of the relevant NTS.
Specific patient groups
Older people - Clinical experience with bupropion has not identified any differences in tolerability between older and other adult patients. However, greater sensitivity of some older individuals cannot be ruled out; hence 150 mg once a day is the recommended dose in these patients.
Patients with hepatic impairment - Bupropion is extensively metabolised in the liver to active metabolites, which are further metabolised. No statistically significant differences in the pharmacokinetics of bupropion were observed in patients with mild to moderate hepatic cirrhosis compared with healthy volunteers, but bupropion plasma levels showed a higher variability between individual patients. Therefore Budeprionsr should be used with caution in patients with mild to moderate hepatic impairment and 150 mg once a day is the recommended dose in these patients.
All patients with hepatic impairment should be closely monitored for possible undesirable effects (e.g., insomnia, dry mouth, seizures) that could indicate high drug or metabolite levels.
Patients with renal impairment - Bupropion is mainly excreted into urine as its metabolites. Therefore 150 mg once a day is the recommended dose in patients with renal impairment, as bupropion and its active metabolites may accumulate to a greater extent than usual. The patient should be closely monitored for possible undesirable effects that could indicate high drug or metabolite levels.
Interference with urine testing
Having an amphetamine-like chemical structure, bupropion interferes with the assay used in some rapid urine drug screens, which can result in false positive readings, particularly for amphetamines. A positive result should usually be confirmed with a more specific method.
Inappropriate routes of administration
Budeprionsr is intended for oral use only. The inhalation of crushed tablets or injection of dissolved bupropion has been reported, and may lead to a rapid release, faster absorption and a potential overdose. Seizures and/or cases of death have been reported when bupropion has been administered intra-nasally or by parenteral injection.
As with other CNS acting drugs bupropion may affect ability to perform tasks that require judgement or motor and cognitive skills. Budeprionsr has also been reported to cause dizziness and lightheadedness. Patients should therefore exercise caution before driving or use of machinery until they are reasonably certain Budeprionsr does not adversely affect their performance.
Posology
Use in Adults
It is recommended that treatment is started while the patient is still smoking and a "target stop date" set within the first two weeks of treatment with Budeprionsr, preferably in the second week.
The initial dose is 150mg to be taken daily for six days, increasing on day seven to 150mg twice daily.
There should be an interval of at least 8 hours between successive doses.
The maximum single dose must not exceed 150mg and the maximum total daily dose must not exceed 300mg.
Insomnia is a very common adverse event which can be reduced by avoiding bedtime doses of Budeprionsr (provided there is at least 8 hours between doses).
Paediatric population
Use in patients under 18 years of age is not recommended as the safety and efficacy of Budeprionsr tablets have not been evaluated in these patients.
Older people
Budeprionsr should be used with caution in older people. Greater sensitivity in some older individuals cannot be ruled out. The recommended dose in older people is 150mg once a day.
Patients with hepatic impairment
Budeprionsr should be used with caution in patients with hepatic impairment. Because of increased variability in the pharmacokinetics in patients with mild to moderate impairment the recommended dose in these patients is 150mg once a day.
Patients with renal impairment
Budeprionsr should be used with caution in patients with renal insufficiency. The recommended dose in these patients is 150mg once a day.
Method of administration
Budeprionsr should be used in accordance with smoking cessation guidelines.
Prescribers should assess the patient's motivation to quit. Smoking cessation therapies are more likely to succeed in those patients whom are motivated to quit and have motivational support.
Patients should be treated for 7-9 weeks. If at seven weeks no effect is seen, treatment should be discontinued.
Budeprionsr tablets should be swallowed whole. The tablets should not be cut, crushed or chewed as this may lead to an increased risk of adverse effects including seizures.
Budeprionsr can be taken with or without food.
Discontinuing therapy
Although discontinuation reactions are not expected with Budeprionsr, a tapering-off period may be considered.
No special requirements for disposal.
